CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F23%3A00131953" target="_blank" >RIV/00216224:14110/23:00131953 - isvavai.cz</a>
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0923753423005744?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0923753423005744?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.annonc.2023.04.432" target="_blank" >10.1016/j.annonc.2023.04.432</a>

Result language
angličtina
Original language name
CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors
Original language description
Solid cancer patients are at high risk of a more severe course of COVID-19, especially those undergoing active anti-cancer therapy causing immunosuppression. Vaccination is still the only option to prevent serious events associated with SARS-CoV-2 infection. We aim to assess adverse effects, efficacy, and immune response against SARS-CoV-2 in cancer patients, focusing on comparison with healthy volunteers and possible interfering therapy.
Czech name
—
Czech description
—

Project
<a href="/en/project/LM2023049" target="_blank" >LM2023049: Czech National Node of the European Clinical Research Infrastructures Network</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)